63 related articles for article (PubMed ID: 20804307)
1. Acid reflux directly causes sleep disturbances in rat with chronic esophagitis.
Nakahara K; Fujiwara Y; Tsukahara T; Yamagami H; Tanigawa T; Shiba M; Tominaga K; Watanabe T; Urade Y; Arakawa T
PLoS One; 2014; 9(9):e106969. PubMed ID: 25215524
[TBL] [Abstract][Full Text] [Related]
2. Modeled Hepatic/Plasma Exposures of Omeprazole Prescribed Alone in Cytochrome P450 2C19 Poor Metabolizers Are Likely Associated with Hepatic Toxicity Reported in a Japanese Adverse Event Database.
Adachi K; Ohyama K; Tanaka Y; Murayama N; Shimizu M; Saito Y; Yamazaki H
Biol Pharm Bull; 2024; 47(5):1028-1032. PubMed ID: 38797695
[TBL] [Abstract][Full Text] [Related]
3. Medical or surgical therapy for erosive reflux esophagitis: cost-utility analysis using a Markov model.
Romagnuolo J; Meier MA; Sadowski DC
Ann Surg; 2002 Aug; 236(2):191-202. PubMed ID: 12170024
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety Profile of Z-215 (Azeloprazole Sodium), a Proton Pump Inhibitor, Compared with Rabeprazole Sodium in Patients with Reflux Esophagitis: A Phase II, Multicenter, Randomized, Double-Blind, Comparative Study.
Kinoshita Y; Kusano M; Iwakiri K; Fujishiro M; Tachikawa N; Haruma K
Curr Ther Res Clin Exp; 2018; 88():26-34. PubMed ID: 30038671
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Helicobacter pylori positive infected patients according to Clarithromycin resistant 23S rRNA, rpl22 associated mutations and cyp2c19*1, *2, *3 genes pattern in the Early stage of Gastritis.
Maghami AA; Mobarez AM; Yadegar A; Nikkhah M; Sadeghi A; Esmaeili S
BMC Res Notes; 2022 Oct; 15(1):335. PubMed ID: 36284359
[TBL] [Abstract][Full Text] [Related]
6. Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
Yadlapati R; DeLay K
Med Clin North Am; 2019 Jan; 103(1):15-27. PubMed ID: 30466671
[TBL] [Abstract][Full Text] [Related]
7. A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease.
Hillman L; Yadlapati R; Thuluvath AJ; Berendsen MA; Pandolfino JE
Dis Esophagus; 2017 Sep; 30(9):1-15. PubMed ID: 28859358
[TBL] [Abstract][Full Text] [Related]
8. Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region.
Dagenais R; Wilby KJ; Elewa H; Ensom MHH
Drugs R D; 2017 Sep; 17(3):341-361. PubMed ID: 28748348
[TBL] [Abstract][Full Text] [Related]
9. Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian population.
Payan M; Rouini MR; Tajik N; Ghahremani MH; Tahvilian R
Daru; 2014 Dec; 22(1):81. PubMed ID: 25498969
[TBL] [Abstract][Full Text] [Related]
10. Antiplatelet drug interactions with proton pump inhibitors.
Scott SA; Owusu Obeng A; Hulot JS
Expert Opin Drug Metab Toxicol; 2014 Feb; 10(2):175-89. PubMed ID: 24205916
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of omeprazole in a random Iranian population.
Ala S; Zanad F; Shiran MR
Caspian J Intern Med; 2013; 4(3):712-6. PubMed ID: 24009966
[TBL] [Abstract][Full Text] [Related]
12. Aurora kinase A (AURKA) and never in mitosis gene A-related kinase 6 (NEK6) genes are upregulated in erosive esophagitis and esophageal adenocarcinoma.
Kasap E; Boyacioglu SO; Korkmaz M; Yuksel ES; Unsal B; Kahraman E; Ozütemiz O; Yuceyar H
Exp Ther Med; 2012 Jul; 4(1):33-42. PubMed ID: 23060919
[TBL] [Abstract][Full Text] [Related]
13. Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19.
Furuta T; Sugimoto M; Shirai N
Mol Diagn Ther; 2012 Aug; 16(4):223-34. PubMed ID: 22873740
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 2C19 Polymorphism in Iranian Patients with Coronary Artery Disease.
Akhlaghi A; Shirani S; Ziaie N; Pirhaji O; Yaran M; Shahverdi G; Sarrafzadegan N; Khosravi A; Khosravi E
ARYA Atheroscler; 2011; 7(3):106-10. PubMed ID: 22577456
[TBL] [Abstract][Full Text] [Related]
15. Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis.
Zendehdel N; Biramijamal F; Hossein-Nezhad A; Zendehdel N; Sarie H; Doughaiemoghaddam M; Pourshams A
Arch Iran Med; 2010 Sep; 13(5):406-12. PubMed ID: 20804307
[TBL] [Abstract][Full Text] [Related]
16. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease.
Lee YC; Lin JT; Wang HP; Chiu HM; Wu MS
J Gastroenterol Hepatol; 2007 Aug; 22(8):1286-92. PubMed ID: 17559380
[TBL] [Abstract][Full Text] [Related]
17. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism.
Kawamura M; Ohara S; Koike T; Iijima K; Suzuki J; Kayaba S; Noguchi K; Hamada S; Noguchi M; Shimosegawa T;
Aliment Pharmacol Ther; 2003 Apr; 17(7):965-73. PubMed ID: 12656699
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
